Blood Test Identifies Prostate Cancer Patients Best Suited for Targeted Radiotherapy
Predicting Treatment Response
A new study published in JAMA Network Open suggests a blood test could guide therapy for men with hormone-resistant prostate cancer. Researchers from The Royal Marsden, The Institute of Cancer Research, and University College London found that measuring circulating tumor DNA (ctDNA) before treatment provides vital insights. These genetic fragments, shed by cancer cells into the bloodstream, reveal tumor activity that remains invisible to standard imaging techniques.
Health news
Exercise and Mood: Italian Study Links Physical Activity to Lower Depression Symptoms
Screen Time in Childhood Linked to Unexpected Cognitive Boost in Teens, 8‑Year Study Shows
Workplace stress and anxiety are taking a heavy toll on employees, with one in three workers reporting that the strain is not easing
Daily Food Habit Tied to Lower Risk of Anxiety and DepressionThe research utilized data from the TRAP clinical trial, which assessed stereotactic body radiotherapy (SBRT) for patients with oligoprogressive, hormone-resistant prostate cancer. This condition occurs when cancer spreads but remains active in fewer than three distinct locations. Participants received targeted radiation to these specific areas while continuing hormone therapies like abiraterone or enzalutamide. Because SBRT is highly focused, there is a risk that cancer may continue growing in areas too small to detect on scans.
The team analyzed pre-treatment blood samples from 77 trial participants, monitoring them for over two years. Nineteen men had detectable ctDNA, while 58 did not. The difference in progression-free survival was stark: those without detectable ctDNA had a median progression-free survival of 7.8 months, compared to only three months for those who tested positive. Six months after treatment, 58% of the negative group remained progression-free, versus 21% of the positive group. These findings remained significant even after adjusting for age, PSA levels, prior chemotherapy, and tumor location.
Significant Clinical Outcomes
These results may help guide future trials on using ctDNA to tailor treatment. Men without detectable ctDNA are more likely to see prolonged control after radiotherapy. Conversely, the presence of ctDNA might indicate that the cancer is active elsewhere, signaling a need to switch medications. Combining blood tests with imaging could lead to more personalized care.
Dr. Alison Tree, chief clinical oncologist at The Royal Marsden and lead investigator of the TRAP trial, noted that this test provides valuable insights into cancer behavior beyond what scans show. While further research is needed, these steps are essential for identifying which patients benefit most from targeted radiotherapy. Dr. Alison Reid, the study's first author, emphasized that a blood-based marker allows clinicians to determine who should continue current hormone therapies alongside SBRT and who requires a new drug.
Patient Tony Sparrow, 73, participated in the TRAP trial after being diagnosed with advanced prostate cancer that had spread to his hip, spine, and groin. He described the SBRT procedure as quick, painless, and effective, with no notable side effects.